Preclinical Evaluation of SPECT Imaging with 131 ∣-Labeled Monoclonal Antibody SZ39 in Nude Mice Bearing Human Glioma Xenografts

1996 ◽  
Vol 6 (2) ◽  
pp. 131-135 ◽  
Author(s):  
Qing Lan ◽  
Qiang Huang ◽  
Shiyao Bao
Keyword(s):  
Monoclonal Antibody ◽  
Nude Mice ◽  
Spect Imaging ◽  
Human Glioma ◽  
Preclinical Evaluation

Radioimmunotherapy of human glioma xenografts in nude mice by indium-111 labelled internalising monoclonal antibody

1999 ◽  
Vol 35 (8) ◽  
pp. 1281-1285 ◽  
Author(s):  
T Saga ◽  
H Sakahara ◽  
Y Nakamoto ◽  
N Sato ◽  
S Zhao ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Nude Mice ◽  
Human Glioma ◽  
Indium 111

Preclinical Evaluation of Monoclonal Antibody 14C5 for Targeting Pancreatic Cancer

2010 ◽  
Vol 25 (2) ◽  
pp. 193-205 ◽  
Author(s):  
Liesbet Vervoort ◽  
Ingrid Burvenich ◽  
Steven Staelens ◽  
Caroline Dumolyn ◽  
Els Waegemans ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Monoclonal Antibody ◽  
Preclinical Evaluation

Tumor targeting therapy using peplomycin-conjugated ST433 monoclonal antibody in nude mice

1988 ◽  
Vol 10 ◽  
pp. 30
Author(s):  
K. Shibuya ◽  
T. Someno ◽  
F. Abe ◽  
T. Setoh ◽  
S. Fukushima ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Nude Mice ◽  
Tumor Targeting ◽  
Targeting Therapy

scholarly journals Repeated Intraperitoneal -Radioimmunotherapy of Ovarian Cancer in Mice

2010 ◽  
Vol 2010 ◽  
pp. 1-5 ◽  
Author(s):  
Jörgen Elgqvist ◽  
Håkan Andersson ◽  
Holger Jensen ◽  
Helena Kahu ◽  
Sture Lindegren ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Monoclonal Antibody ◽  
Cell Line ◽  
Nude Mice ◽  
Therapeutic Efficacy ◽  
Therapeutic Index ◽  
Repeated Treatment ◽  
Treatment Regimens ◽  
Potential Increase

The aim of this study was to investigate the therapeutic efficacy of -radioimmunotherapy of ovarian cancer in mice using different fractionated treatment regimens. The study was performed using the monoclonal antibody MX35 F labeled with the -particle emitter .Methods. Nude mice were intraperitoneally inoculated with ~ cells of the cell line NIH:OVCAR-3. Four weeks later 6 groups of animals were given F as a single or as a repeated treatment of up to 6 times ( in each group). The fractionated treatments were given every seventh day. Control animals were treated with unlabeled F (). Eight weeks posttreatment the animals were sacrificed and the presence of macro- and microscopic tumors and ascites was determined.Results. The tumor-free fractions (TFFs) of the animals, defined as the fraction of animals with no macro- and microtumors and no ascites, were 0.17, 0.11, 0.39, 0.44, 0.44, and 0.67 when treated with F once or 2, 3, 4, 5, or 6 times, respectively. Repeated treatment 3 times or more resulted in a significantly higher () TFF than compared to treatment once or twice. The presence of ascites decreased from 15 out of 18 animals in the group given only one treatment to zero for the 2 groups given 5 or 6 fractions. Treatment with unlabeled F resulted in a TFF of zero.Conclusion. Weekly repeated intraperitoneal injections of tolerable amounts of activity of F of up to 6 times produced increased therapeutic efficacy without observed toxicity, indicating a potential increase of the therapeutic index.

scholarly journals Preclinical evaluation of89Zr-labeled anti-CD44 monoclonal antibody RG7356 in mice and cynomolgus monkeys

mAbs ◽  
2013 ◽  
Vol 6 (2) ◽  
pp. 567-575 ◽  
Author(s):  
Danielle J Vugts ◽  
Derrek A Heuveling ◽  
Marijke Stigter-van Walsum ◽  
Stefan Weigand ◽  
Mats Bergstrom ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Cynomolgus Monkeys ◽  
Preclinical Evaluation
Sign in / Sign up

Export Citation Format

Share Document